Family History Increases Cancer Risk in BRCA-Tested Patients
On Jul. 30, 2026, a study led by Cedars-Sinai Health Sciences University investigators found that women who test…
-
-
FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer
On Jul. 14, 2026, the Food and Drug Administration approved gedatolisib (Revtorpyk, Celcuity) in combination with fulvestrant, with…
-
EU Approves first tumour agnostic HER2-directed therapy for Breast Cancer
On Jun. 29, 2026, AstraZeneca and Daiichi Sankyo’s announced that Enhertu (trastuzumab deruxtecan) had been approved in the…
-
U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
On Jun. 24, 2026, Gilead Sciences announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvy®…
-
Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer
On May 22, 2026, Gilead Sciences announced that the Committee for Medicinal Products for Human Use (CHMP) of…
-
BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS(TM) Patient
On Jan. 13, 2026, BriaCell Therapeutics announces the durable and sustained complete resolution of a lung metastasis in…
-
Diagnostics | Disease | Medical Device | Medicine | NIH | Non-Profit Research | Oncology | Radiology | Therapeutics | U.S. Congress | Women's Health
American Cancer Society Reports a Milestone 70 Percent 5-Year Survival Rate for all Cancers Combined
On Jan. 13, 2026, The American Cancer Society (ACS) released Cancer Statistics, 2026, the organization’s annual report on cancer facts and trends. The findings show, for…
-
CPRIT approves $154 million in new cancer research and prevention awards, surpasses $4 billion total
On Nov. 19, 2025, the governing board of the Cancer Prevention and Research Institute of Texas (CPRIT) approved…
-
GRAIL PATHFINDER 2 Results Show Galleri ® Multi-Cancer Early Detection Blood Test Increased Cancer Detection
On Oct. 18, 2025, GRAIL announced that positive performance and safety results from its registrational PATHFINDER 2 study…
-
Celltrion USA announces U.S. launch of denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo)
On Jul. 7, 2025, Celltrion announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing PROLIA® (denosumab) and XGEVA® (denosumab)…
-
Biotechnology | CDC | COVID-19 | Diagnostics | Disease | Genomics | NIH | Oncology | Radiology | Women's Health
Annual Report to the Nation Shows Cancer Deaths Continue to Decline
On Apr. 21, 2025, the National Institutes of Health (NIH) reported that overall death rates from cancer declined steadily among…
-
Thousands of people could benefit from new twice-a-day tablet for advanced breast cancer
On Apr. 11, 2025, the UK National Institute for Health and Care Excellence (NICE) recommended capivasertib (also called…
-
Roswell Park Team Identifies New Cause of Chemotherapy Resistance in Triple-Negative Breast Cancer
On Jan. 10, 2025, researchers at Roswell Park Comprehensive Cancer Center have identified a previously unknown cause of…
-
U.S. Surgeon General Issues New Advisory on Link Between Alcohol and Cancer Risk
On Jan. 3, 2025, the U.S. General Dr. Vivek Murthy released a new Surgeon General’s Advisory on Alcohol…
-
Biotechnology | Diagnostics | Disease | Oncology | Vaccine | Women's Health
Anixa Biosciences and Cleveland Clinic Presented Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine
On Nov. 8, 2024, Anixa Biosciences announced updated positive data from the Phase 1 clinical trial of its…
-
Biotechnology | Disease | FDA | Oncology | Therapeutics
FDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
On Oct. 10, 2024, Genentech announced today that the U.S. Food and Drug Administration (FDA) approved ItovebiTM (inavolisib),…
-
Breast Cancer Mortality Continues Three Decade Decline, but Steeper Increases in Incidence for Women <50
On Oct. 1, 2024, the American Cancer Society (ACS) released Breast Cancer Statistics, 2024, the organization’s biennial update…
-
Biotechnology | COVID-19 | Diagnostics | NIH | Oncology | Therapeutics | Women's Health
New cancer diagnoses did not rebound as expected following pandemic
On Sept. 24, 2024, researchers at the National Institutes of Health (NIH) reported results of a study that…
-
Breast and ovarian cancer linked to thousands of gene variants
On Sept. 18, 2024, researchers from the Wellcome Sanger Institute and their collaborators reported that they had identified…
-
False-positive mammogram results discourage some women from future screenings
On Sept. 3, 2024, a major study led by the UC Davis Comprehensive Cancer Center (UC DAVIS) has…
-
Biotechnology | Diagnostics | Disease | NIH | Oncology | Radiology | Therapeutics | Women's Health
NCI’s Cancer Trends Progress Report announced 2023 Incidence and Mortality Data
On Sep. 3, 2024, the National Cancer Institute (NCI) announced that the latest Cancer Trends Progress Report included…
-
Generation X and Millennials in U.S. Have Higher Risk of Developing 17 Cancers Compared to Older Generations
On Jul. 31, 2024, a large study led by researchers at the American Cancer Society (ACS) suggested incidence…
-
Biotechnology | Diagnostics | Disease | Oncology | Therapeutics | WHO
Nearly 1.8 billion adults at risk of disease from not doing enough physical activity
On Jun. 26. 2024, the World Health Organization reported that new data show that nearly one third (31%)…
-
Biotechnology | Disease | Life Science History | NIH | Oncology | Radiology | Therapeutics | Women's Health
American Association for Cancer Research released biennial Cancer Disparities Progress Report 2024
On May 15, 2024, the American Association for Cancer Research (AACR) released its biennial Cancer Disparities Progress Report…
-
Clinical Research | Diagnostics | Disease | NIH | Non-Profit Research | Oncology | Radiology | Therapeutics | Women's Health
Researchers reviewed findings and clinical messages from the Women’s Health Initiative 30 years after launch
On May 1, 2024, researchers at the National Institutes of Health (NIH) announced a review in JAMA that…
-
U.S. Preventive Services Task Force recommended all women get screened for breast cancer every other year aged 40 to 74
On Apr. 30, 2024, the U.S. Preventive Services Task Force (USPSTF) recommended that all women get screened for…
-
Biotechnology | Diagnostics | Disease | Oncology | Vaccine | Women's Health
Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine
On Dec. 6, 2023, Anixa Biosciences announced updated positive results from the Phase 1 clinical trial of its…
-
Biotechnology | Diagnostics | Disease | FDA | Oncology | Radiology | Therapeutics | Women's Health
FDA Cleared 23andMe improved BRCA report for communities underrepresented in genetic testing
On Aug. 31, 2023, the U.S. Food and Drug Administration (FDA) cleared for marketing the updated 23andMe Personal…
-
Biotechnology | Diagnostics | Disease | FDA | Oncology | Radiology | Therapeutics | Women's Health
FDA updated mammography regulations to require reporting of breast density information and facility oversight
On Mar. 9, 2023, the U.S. Food and Drug Administration (FDA) announced that it had published updates to…
-
Biotechnology | Diagnostics | Disease | Oncology | Radiology | Therapeutics | WHO | Women's Health
WHO launched new roadmap on breast cancer
On Feb. 3, 2023, the World Health Organization (WHO) released an updated Global Breast Cancer Initiative (GBCI) Framework…
